Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 129 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014', provides an overview of the Bipolar Disorder (Manic Depression)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Bipolar Disorder (Manic Depression) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Bipolar Disorder (Manic Depression) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bipolar Disorder (Manic Depression) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bipolar Disorder (Manic Depression)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Bipolar Disorder (Manic Depression) Overview 10
Therapeutics Development 11
Pipeline Products for Bipolar Disorder (Manic Depression) - Overview 11
Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis 12
Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies 13
Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes 16
Bipolar Disorder (Manic Depression) - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Bipolar Disorder (Manic Depression) - Products under Development by Companies 21
Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes 22
Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development 23
AstraZeneca PLC 23
Eli Lilly and Company 24
Sumitomo Dainippon Pharma Co., Ltd. 25
Takeda Pharmaceutical Company Limited 26
Zogenix, Inc. 27
Richter Gedeon Nyrt. 28
Pfizer Inc. 29
Teva Pharmaceutical Industries Limited 30
Transition Therapeutics Inc. 31
Intas Pharmaceuticals Ltd. 32
D-Pharm Ltd. 33
Omeros Corporation 34
Intra-Cellular Therapies, Inc. 35
KemPharm, Inc. 36
Ascendis Pharma A/S 37
Otsuka Holdings Co., Ltd. 38
Reviva Pharmaceuticals Inc. 39
MarcoPolo Pharmaceuticals SA 40
Delpor, Inc. 41
Zysis Limited 42
Convergence Pharmaceuticals Ltd. 43
SK Biopharmaceuticals Co., Ltd. 44
Bipolar Disorder (Manic Depression) - Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 49
Assessment by Route of Administration 52
Assessment by Molecule Type 54
Drug Profiles 56
aripiprazole - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
quetiapine fumarate ER - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ramelteon - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ELND-005 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ziprasidone hydrochloride - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
cariprazine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
YKP-3089 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Endoxifen - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ITI-007 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DP-VPA - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
LY-2979165 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
risperidone - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Drug for Cancer and Neurodegenerative Disease - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
aripiprazole CR - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
lurasidone hydrochloride - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
SKL-PSY - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
NP-202 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
ACP-005 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecule to Target GPR50 for CNS and Metabolic Disorders - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
risperidone - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
paliperidone - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
CNV-1061436 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
PGW-5 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
KP-303 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
MP-03 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Synthetic Peptides to inhibit IMPase for Bipolar Disorder - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
BRDK-98958073 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
RP-5063 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Bipolar Disorder (Manic Depression) - Recent Pipeline Updates 98
Bipolar Disorder (Manic Depression) - Dormant Projects 115
Bipolar Disorder (Manic Depression) - Discontinued Products 116
Bipolar Disorder (Manic Depression) - Product Development Milestones 117
Featured News & Press Releases 117
May 01, 2014: Dainippon Sumitomo Pharma Announces Health Canada Approval of LATUDA (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Patients with Bipolar Depression 117
Apr 07, 2014: Transition Therapeutics Announces Development Update 117
Mar 31, 2014: Forest Laboratories and Gedeon Richter Announce Positive Phase IIb Topline Results for Cariprazine for the Treatment of Bipolar Depression 119
Nov 01, 2013: Sunovion Announces Publication of Two Pivotal Studies Supporting FDA Approval of Latuda as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression in The American Journal of Psychiatry 120
Oct 29, 2013: A Phase I ready novel sodium channel blocker CNV1061436 for CNS disorders is added to the pipeline of clinical development candidates 122
Oct 24, 2013: Otsuka announces 2013 third quarter U.S. net sales figures of ABILIFY 122
Aug 30, 2013: Teva Reports Top-Line Results from Final Phase III Study of Armodafinil (NUVIGIL) in Patients with Major Depression Associated with Bipolar I Disorder 123
Jun 28, 2013: Sunovion Pharmaceuticals Announces FDA Approval of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression 123
Jun 18, 2013: Bipartisan Coalition Of Attorneys General And State Legislators Request Supreme Court To Uphold $1.2 billion Judgment In Janssen Risperdal Lawsuit 125
Jun 06, 2013: NICE Proposes To Recommend Otsuka Pharma's Aripiprazole For Treatment For Children With Bipolar Disorder 126
Appendix 128
Methodology 128
Coverage 128
Secondary Research 128
Primary Research 128
Expert Panel Validation 128
Contact Us 129
Disclaimer 129

List of Tables
Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2014 11
Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2014 12
Number of Products under Development by Companies, H2 2014 14
Number of Products under Development by Companies, H2 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2014 16
Comparative Analysis by Late Stage Development, H2 2014 17
Comparative Analysis by Clinical Stage Development, H2 2014 18
Comparative Analysis by Early Stage Development, H2 2014 19
Comparative Analysis by Unknown Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Investigation by Universities/Institutes, H2 2014 22
Bipolar Disorder (Manic Depression) - Pipeline by AstraZeneca PLC, H2 2014 23
Bipolar Disorder (Manic Depression) - Pipeline by Eli Lilly and Company, H2 2014 24
Bipolar Disorder (Manic Depression) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 25
Bipolar Disorder (Manic Depression) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 26
Bipolar Disorder (Manic Depression) - Pipeline by Zogenix, Inc., H2 2014 27
Bipolar Disorder (Manic Depression) - Pipeline by Richter Gedeon Nyrt., H2 2014 28
Bipolar Disorder (Manic Depression) - Pipeline by Pfizer Inc., H2 2014 29
Bipolar Disorder (Manic Depression) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 30
Bipolar Disorder (Manic Depression) - Pipeline by Transition Therapeutics Inc., H2 2014 31
Bipolar Disorder (Manic Depression) - Pipeline by Intas Pharmaceuticals Ltd., H2 2014 32
Bipolar Disorder (Manic Depression) - Pipeline by D-Pharm Ltd., H2 2014 33
Bipolar Disorder (Manic Depression) - Pipeline by Omeros Corporation, H2 2014 34
Bipolar Disorder (Manic Depression) - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 35
Bipolar Disorder (Manic Depression) - Pipeline by KemPharm, Inc., H2 2014 36
Bipolar Disorder (Manic Depression) - Pipeline by Ascendis Pharma A/S, H2 2014 37
Bipolar Disorder (Manic Depression) - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 38
Bipolar Disorder (Manic Depression) - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 39
Bipolar Disorder (Manic Depression) - Pipeline by MarcoPolo Pharmaceuticals SA, H2 2014 40
Bipolar Disorder (Manic Depression) - Pipeline by Delpor, Inc., H2 2014 41
Bipolar Disorder (Manic Depression) - Pipeline by Zysis Limited, H2 2014 42
Bipolar Disorder (Manic Depression) - Pipeline by Convergence Pharmaceuticals Ltd., H2 2014 43
Bipolar Disorder (Manic Depression) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 44
Assessment by Monotherapy Products, H2 2014 45
Number of Products by Stage and Target, H2 2014 48
Number of Products by Stage and Mechanism of Action, H2 2014 51
Number of Products by Stage and Route of Administration, H2 2014 53
Number of Products by Stage and Molecule Type, H2 2014 55
Bipolar Disorder (Manic Depression) Therapeutics - Recent Pipeline Updates, H2 2014 98
Bipolar Disorder (Manic Depression) - Dormant Projects, H2 2014 115
Bipolar Disorder (Manic Depression) - Discontinued Products, H2 2014 116